Bausch Health Cos (NYSE:BHC) Issues Earnings Results

Key Points

• Bausch Health Cos reported quarterly earnings of $0.90 per share, missing the consensus estimate of $0.97 by $0.07, despite achieving revenue of $2.57 billion compared to expected $2.47 billion.
• Insider trading activity shows Director John Paulson increased his stake by 12.19%, acquiring over 3.5 million shares valued at approximately $21.17 million.
• Analysts have mixed ratings on Bausch Health, with one evaluation lowering its stock from "buy" to "hold" and an average price target set at $7.38.

Bausch Health Cos (NYSE:BHC - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.97 by ($0.07), Zacks reports. Bausch Health Cos had a negative return on equity of 522.39% and a net margin of 0.99%. The company had revenue of $2.57 billion for the quarter, compared to analysts' expectations of $2.47 billion. Bausch Health Cos updated its FY 2025 guidance to EPS.

Bausch Health Cos Price Performance

Bausch Health Cos stock opened at $5.89 on Friday. The business has a 50 day simple moving average of $5.95 and a 200-day simple moving average of $6.11. Bausch Health Cos has a 12 month low of $4.25 and a 12 month high of $9.85. The stock has a market capitalization of $2.18 billion, a PE ratio of 22.64 and a beta of 0.41.

Insider Buying and Selling at Bausch Health Cos

In other news, Director John Paulson acquired 3,564,059 shares of the company's stock in a transaction on Friday, June 13th. The shares were bought at an average cost of $5.94 per share, with a total value of $21,170,510.46. Following the purchase, the director owned 32,791,702 shares of the company's stock, valued at $194,782,709.88. This represents a 12.19% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired 6,352,667 shares of company stock worth $35,870,767 over the last three months. 8.05% of the stock is owned by company insiders.

Institutional Trading of Bausch Health Cos

Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its holdings in Bausch Health Cos by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company's stock worth $6,136,000 after purchasing an additional 467,270 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of Bausch Health Cos by 1,548.9% during the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company's stock worth $162,000 after buying an additional 23,451 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Bausch Health Cos during the 1st quarter worth approximately $68,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Bausch Health Cos by 3.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company's stock valued at $2,102,000 after buying an additional 9,834 shares during the period. Institutional investors and hedge funds own 78.65% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on BHC shares. Royal Bank Of Canada lifted their price target on shares of Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Wall Street Zen cut Bausch Health Cos from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. One analyst has rated the stock with a sell rating and five have assigned a hold rating to the company's stock. According to data from MarketBeat, Bausch Health Cos has an average rating of "Hold" and a consensus price target of $7.38.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.